The effect and molecular action of curcumin in FDA-approved clinical drug-treated human bladder cancer cells
碩士 === 國立臺灣師範大學 === 人類發展與家庭學系 === 102 === Bladder cancer is the ninth most common cancer worldwide and the fourteenth most diagnosed malignancy in Taiwan (2013). Gemcitabine plus cisplatin (GC) treatment is prefered for nowadays treatment. For patients with impaired renal function, gemcitabine plus...
Main Authors: | Ya-Wen Fan, 范雅雯 |
---|---|
Other Authors: | Chun-Li Su |
Format: | Others |
Language: | zh-TW |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/63474138092702105330 |
Similar Items
-
Announcement Effect of Drug Approvals by FDA
by: Ting, Hsiu Wen, et al.
Published: (2008) -
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
by: Becky A. S. Bibby, et al.
Published: (2021-07-01) -
The role of KRAS gene in combination treatment of Curcumin and FDA-approved Targeted Drugs in human colorectal cancer cells
by: Wu, Chi-Shiuan, et al.
Published: (2016) -
Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
by: Ashwini eBenedict, et al.
Published: (2015-07-01) -
Quantitative analysis on the characteristics of targets with FDA approved drugs
by: Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar
Published: (2008-01-01)